Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Max-Planck-Institute of Psychiatry German Research Foundation |
---|---|
Information provided by: | Max-Planck-Institute of Psychiatry |
ClinicalTrials.gov Identifier: | NCT00447512 |
Ghrelin, an acylated peptide consisting of 28 amino acids, is the endogenous ligand of the growth hormone secretagogue receptor (GHS-R). It is synthesized predominantly in the stomach but has been also identified in a variety of other organs. Alike, a wide range of central and peripheral endocrine and non-endocrine actions has been described, e. g. being a releasing factor of growth hormone, prolactin and ACTH, a modulator of cell proliferation and apoptosis, a regulator of sleep-wake regulation, and a orexigenic hormone. Aims of this study are:
A) To determine the effect of exogenous ghrelin on sleep-EEG variables and hormones of the hypothalamic-pituitary-adrenocortical (HPA) axis, the gonadotropic axis and the hypothalamic-pituitary-gonadal axis in healthy subjects of both genders (age groups: 20-30, 35-45, 60-70 years).
B) To determine the effect of exogenous ghrelin on sleep-EEG variables and hormones of the HPA axis, the gonadotropic axis and the hypothalamic-pituitary-gonadal axis in patients with major depression (age range: 20-65 years).
Condition | Intervention |
---|---|
Healthy Major Depression |
Drug: ghrelin |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Single Blind (Subject), Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones |
Estimated Enrollment: | 80 |
Study Start Date: | March 2004 |
Study Completion Date: | October 2007 |
Ages Eligible for Study: | 20 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Max Planck Institute of Psychiatry | |
Munich, Germany, 80804 |
Principal Investigator: | Professor Axel Steiger, MD | Max-Planck-Institute of Psychiatry |
Study ID Numbers: | L2/2003 |
Study First Received: | March 13, 2007 |
Last Updated: | October 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00447512 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Depression Mental Disorders Mood Disorders Healthy |
Depressive Disorder, Major Depressive Disorder Behavioral Symptoms |